comprehensive -WSS

comprehensive

author：fashion 2025-09-29 13:31:09 - browse：2

Pascal Soriot - Senate Finance Committee — AstraZeneca CEO Pascal Soriot Jacquelyn Martin/AP

LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly.

Last week, Medicare made its first offers to the makers of the 10 products subject to negotiation, though it said it would be up to the companies to discuss the proposals. On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga.

“We have received the first offer, but as you can imagine, we will not disclose what the offer is,” Ruud Dobber, the company’s executive vice president of biopharmaceuticals business, said at the event, held at the London Stock Exchange. “We are in active negotiation, and it will be a few rounds of discussions” with Medicare.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Why we need mandatory labeling of GMO products

hotspot

WSS

ASCO Daily Recap: CAR

Clinicians often fail to acknowledge the pain caused by long Covid

Data don't support strong claims for Covid

Lawsuit challenges CMS nursing home minimum staffing rule

J&J reports mixed data on next

CMS got Medicare Advantage quality rating wrong, judge rules

focus

comprehensive

Wikipedia

As demand for Covid shots wanes, Moderna seeks its next success

Elevance PBM president out as customers face prescription chaos

DIEP, the 'gold standard' of breast reconstruction, is under threat

Structure Therapeutics oral GLP

Jerome Adams on the need for new antivirals for Covid

Louisiana bill approved classifying abortion pills as controlled substances

Hollywood unions extend contract negotiations for actors

Elevance PBM president out as customers face prescription chaos

Medicare details structure of new drug price negotiation program

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

entertainment

Illumina board agrees to spin off Grail, as divestment plans proceed

STAT wants to know your pick for a great summer read or listen

New research sheds light on how often breast cancer is overdiagnosed

Stroke rates rising, especially in working

Congress: Prevent baby formula shortages by passing a new bill

Louisiana bill approved classifying abortion pills as controlled substances

hotspot

focus

hotspot

focus